September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Ocular Safety of Intravitreal Anti Connective Tissue Growth Factor Neutralizing Antibody
Author Affiliations & Notes
  • Narsis Daftarian
    Ophthalmology, Ophthalmic Research Center, SBMU, Tehran, Tehran, Iran (the Islamic Republic of)
    Ophthalmology, Ocular Tissue Engineering Research Center, SBMU, Tehran, Iran (the Islamic Republic of)
  • Tahmineh Motevasseli
    Ophthalmology, Ophthalmic Research Center, SBMU, Tehran, Tehran, Iran (the Islamic Republic of)
  • Abouzar Bagheri
    Ophthalmology, Ocular Tissue Engineering Research Center, SBMU, Tehran, Iran (the Islamic Republic of)
    Genetics, 3-University of Social Welfare and Rehabilitation Sciences, Tehran, Iran (the Islamic Republic of)
  • Mozhgan Rezaeikanavi
    Ophthalmology, Ocular Tissue Engineering Research Center, SBMU, Tehran, Iran (the Islamic Republic of)
  • Hamid Ahmadieh
    Ophthalmology, Ophthalmic Research Center, SBMU, Tehran, Tehran, Iran (the Islamic Republic of)
    Ophthalmology, Ocular Tissue Engineering Research Center, SBMU, Tehran, Iran (the Islamic Republic of)
  • Zahra-Soheila Soheili
    Genetics, 4- National Institute of Genetic Engineering and Biotechnology, Tehran, Iran (the Islamic Republic of)
  • Footnotes
    Commercial Relationships   Narsis Daftarian, None; Tahmineh Motevasseli, None; Abouzar Bagheri, None; Mozhgan Rezaeikanavi, None; Hamid Ahmadieh, None; Zahra-Soheila Soheili, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3285. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Narsis Daftarian, Tahmineh Motevasseli, Abouzar Bagheri, Mozhgan Rezaeikanavi, Hamid Ahmadieh, Zahra-Soheila Soheili; Ocular Safety of Intravitreal Anti Connective Tissue Growth Factor Neutralizing Antibody. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3285.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Connective tissue growth factor (CTGF) is the major pro fibrotic growth factor associated with the wide variety of fibrotic disorders such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR). We have previously shown that application of 10 μg of anti-CTGF neutralizing antibody in combination with 0.8 mg of bevacizumab in 1 ml of retinal pigment epithelium cell culture decreased CTGF gene and protein expression. In the present study we determine the maximum safe dose of intravitreal injection of anti-CTGF (IVAC) in rat eyes.

Methods : 45 Lister Hooded pigmented rats were divided into five groups; 4 of these groups received IVAC (1 μl) corresponding to doses of 10 μg (B), 20 μg (C), 50 μg (D), and 100 μg (E), respectively. The sham group (A) received 1 µl of normal saline. Full field electroretinography (ERG) was performed at baseline and at days 7 and 28 after IVAC. The animals were euthanized and the corresponding eyes were subjected to routine histopathology, immunohistochemistry for Glial Fibrillary Acidic Protein (GFAP), and TUNNEL assay.

Results : Scotopic rod b wave amplitude and maximal combined b wave amplitude were 111.89±71.2µv and 178.57 ± 55.58 µv respectively at baseline which reduced significantly after 28 days (79.31 ± 52.59 µv and 128.73 ± 41.61 µv, respectively) in the group E with 100 µg/µl of IVAC (P<0.05) . There was no significant reduction of amplitudes in other groups with lower doses of anit-CTGF antibody and in the sham group. Reduction in oscillatory potentials was also noticed after 7 and 28 days in the group E (46.24±18.05 µv at baseline, 30.03±15.95 µv at 7 days, P<0.05 and 29.79±12.20 µv at 28 days, P<0.001) but not in other groups. Photopic ERG responses did not show any significant change in any groups. Excepting 4 out of 9 eyes in group E that revealed retinal inner nuclear and ganglion cell layer atrophic changes, histologic findings were unremarkable in other groups. GFAP immune reactivity was not significant in any of the groups. TUNNEL test showed inner retinal neural cell apoptosis in group E, but not in other groups.

Conclusions : ERG, histopathologic, and apoptotic assays revealed no toxic effects of 10 to 50 µg/µl IVAC in the rat eyes. A significant toxic effect was observed after100 µg/µl IVAC in terms of both functional and histopathologic findings.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×